Mandate

Vinge advises Adelis in connection with the acquisition of Logent

November 12, 2013

Vinge is advising Adelis Equity Partners Fund 1 AB in connection with its acquisition of Logent AB (“Logent”) from the company’s two founders and Inter IKEA Investments AB. The acquisition is taking place together with the company’s management. It is anticipated that the transaction will be completed by the end of November 2013. Logent was founded in 2006 and has had growth in sales over the last five years of more than 60% per year, both organically and as a result of strategic acquisitions. Logent currently has an extensive network of on-site solutions in Sweden and Norway and has approximately 3500 employees. Logent’s turnover for 2013 is expected to amount to approximately SEK 1.3 billion.

Vinge’s team consists of responsible partner Christina Kokko together with Johan Mattsson and Gustav Jönsson. Partner Mikael Ståhl and associates Sofia Graflund and Emelie Klefbeck advised on acquisition financing issues. Partners Mattias Scömer, Odile Fallenius and Johan Larsson and associates Ulf Nilsson and Emelie Parland advised Adelis in relation to funds, tax, and VAT issues.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026